I. PURPOSE

To define and describe the accepted indications for Arzerra (ofatumumab) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR

2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies AND

4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND

5. When available, generic alternatives are preferred over brand-name drugs.

B. Chronic Lymphocytic Leukemia (CLL)

1. NOTE: Per NCH Policy and NCH Pathways, Arzerra (ofatumumab) is not recommended for use in CLL. Several alternative/superior options are available. Please refer to the NCH Pathway document for details.

2. Arzerra (ofatumumab) may be used in members with CLL if all other available or recommended therapies have failed or are contraindicated.

III. EXCLUSION CRITERIA

A. Member has disease progression while taking Arzerra (ofatumumab).

B. Dosing exceeds single dose limit of Arzerra (ofatumumab) 2000 mg.

C. Treatment with Arzerra (ofatumumab) exceeds the maximum duration limit of 12 doses over 24 weeks for previously treated CLL or maximum 12 cycles for previously untreated CLL.

D. Treatment with Arzerra (ofatumumab) exceeds the maximum duration limit of 2 years for extended treatment in CLL.

E. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT

A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

A. Review – Utilization Management Department

B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

A. None

VII. REFERENCES


